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Summary  
The diagnosis of multiple sclerosis (MS) is based on typical neurological symptoms and 
signs along with evidence of dissemination of central nervous system (CNS) lesions in space 
and time. Magnetic resonance imaging (MRI) is often sufficient to confirm the diagnosis 
when characteristic lesions of MS accompany a typical clinical syndrome, but in some 
patients, further supportive information can be obtained from cerebrospinal fluid examination 
and neurophysiological testing. It is important to differentiate MS not only from other 
diseases in which demyelination is a feature e.g. neuromyelitis spectrum disorder (NMOSD) 
and acute disseminated encephalomyelitis (ADEM), but also non-demyelinating conditions 
such as chronic small vessel disease and other inflammatory, granulomatous, infective, 
metabolic and genetic causes that can mimic MS. Advances in MRI, serological and genetic 
tests have greatly helped in distinguishing MS from these conditions, but misdiagnosis can 
occur. In this review, we explore the progress and challenges in the diagnosis of MS with 
reference to diagnostic criteria, important differential diagnoses, current controversies and 
uncertainties, and future prospects. 
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Introduction 
Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disorder of the central 
nervous system (CNS). MS can present with alterations in sensation, mobility, balance, 
sphincter function, vision and cognition. Although the course is highly variable, many people 
develop irreversible disability, and MS remains a leading cause of neurological disability in 
young adults. 
 
MS is classified based on the initial disease course as either relapsing-remitting (RRMS) or 
primary progressive (PPMS). RRMS is more common affecting 85-90% of patients and is 
characterised by relapses (episodes of neurologic dysfunction lasting at least 24 hours in the 
absence of fever or infection1) followed by periods of remission. Recovery from relapses is 
variable and may be incomplete.2 RRMS typically affects young adults (mean age at onset 
30 years) and women are affected three times as commonly as men.3 There is evidence that 
the incidence of RRMS may be increasing, particularly in women.3 PPMS (10-15% of 
patients) is characterised by an insidious, slowly progressive increase in neurological 
disability over time, usually without relapses.2 PPMS typically presents at an older age than 
RRMS (mean age at onset 40 years) and there is no gender bias. People with RRMS may 
develop a progressive course with time (secondary progressive MS) with a gradual increase 
in disability with or without relapses.2  
 
An early and accurate diagnosis of MS is essential because there are now effective 
treatments for RRMS. Currently, the diagnosis is based on clinical symptoms and signs and 
magnetic resonance imaging (MRI), which is highly sensitive to the detection of 
characteristic CNS lesions.1 Advances in MRI, immunological and genetic tests have 
improved the diagnosis of other conditions that can be mistaken for MS. A major discovery 
was the association between neuromyelitis optica spectrum disorder (NMOSD) and serum 
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aquaporin-4 IgG (AQP4-IgG), confirming that NMOSD is a different disease from MS 
requiring distinct treatments.4   
 
In this review, we discuss the diagnosis of MS including the approach to investigating 
patients with suspected MS, the diagnostic criteria for MS and their application in clinical 
practice. We cover key MS differential diagnoses with particular focus on other idiopathic 
inflammatory disorders including acute disseminated encephalomyelitis (ADEM) and 
NMOSD . Finally, we consider areas of controversy and uncertainty and the potential for 
future changes in diagnostic criteria.  
 
Diagnosis of MS  
Presenting symptoms of MS 
The initial presentation of MS is varied and depends both on the location of lesions within the 
CNS and their onset (relapsing or progressive). Patients can present to a variety of doctors 
depending on the nature of their symptoms (e.g. GPs, ophthalmologists, orthopaedic 
surgeons) and if MS is suspected prompt referral to a neurologist is indicated.  
 
Some common presenting symptoms and signs of MS and those either less common or 
suggestive of an alternative diagnosis are shown in Table 1. A first episode of neurologic 
dysfunction, presumably due to RRMS, is called a clinically isolated syndrome (CIS).2,5 
Common CIS presentations include acute unilateral optic neuritis, a partial myelitis or a 
brainstem syndrome.5 Clinical features that suggest demyelination as the cause of such an 
episode include age <40 years, an acute/subacute onset over hours to days, maximal deficit 
within 4 weeks of onset and spontaneous remission. The onset of PPMS in contrast is 
characterised by slowly progressive symptoms, most often an asymmetric paraparesis that 
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evolves over months or years6 or, less commonly, a progressive hemiparesis or cerebellar 
ataxia or very rarely, visual failure or dementia.6  
 
In assessing a patient with suspected MS it is important to determine the onset and evolution 
of their symptoms and to seek details of previous neurological symptoms that could indicate 
an earlier unrecognised attack that may help establish the diagnosis and disease course 
(relapse or progressive onset). The neurological examination is important to localise the site 
of involvement in the CNS and may provide evidence of other lesions, for example 
pathologically brisk reflexes or an extensor plantar response in a patient with optic neuritis.  
 
Approach to investigating patients with suspected MS 
When a patient presents with symptoms or signs that could indicate MS, an MRI is essential 
as an abnormal brain MRI is seen in virtually all patients with established MS7 and over 80% 
of CIS patients who develop MS.8 MRI is also helpful in excluding other pathologies, for 
example, a compressive lesion in a patient with a progressive myelopathy, or identifying 
abnormalities that suggest an alternative diagnosis (e.g. leptomeningeal enhancement, 
longitudinally-extensive spinal cord lesion).  
 
Brain MRI in MS typically shows multifocal T2-hyperintense white matter lesions (Figure 1) in 
characteristic locations: periventricular (including the corpus callosum), juxtacortical (abutting 
the cerebral cortex) and infratentorial regions.9 On T1-weighted images, lesions may appear 
hypointense (T1 “black holes”). Spinal cord lesions occur in 80-90% of patients with 
established MS and up to half of patients with CIS, most often in the cervical cord.10,11 
Lesions extend over <1-2 vertebral segments and are often eccentrically placed abutting the 
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pial surface. Brain and spinal cord lesions may show enhancement after the administration 
of gadolinium (Figure 1).  
 
A standardised MRI protocol was recently proposed by the MAGNIMS network to assist in 
the diagnosis of MS.12 In addition to obtaining brain images with an axial orientation, a 
sagittal T2 fluid-attenuated inversion recovery (FLAIR) sequence is recommended for 
detecting juxtacortical and corpus callosum lesions, which can be helpful in differentiating 
MS from other disorders.12,13 A post-contrast T1-weighted scan is recommended in patients 
with brain MRI lesions, to assist in diagnosis and differential diagnosis.12 Spinal cord MRI is 
recommended in patients with myelopathy or when MRI brain findings are not diagnostic of 
MS.12  
 
In most patients with a typical clinical picture and MRI findings a Cerebrospinal fluid (CSF) 
examination is usually not necessary, but can provide supportive evidence of MS. CSF 
findings in MS include a normal or mildly raised white cell count (<25 cells/cm3, 
predominantly lymphocytes) and protein (usually <1g/L), a raised IgG index and IgG 
oligoclonal bands (OCBs) not present in serum.14 Qualitative assessment of IgG using 
isoelectric focusing and immunofixation is the optimal method for detection of OCBs.14 OCBs 
are found in up to 90% of people with MS (less often in CIS patients)15 and sometimes in 
other neuroinflammatory disorders and their presence needs to be interpreted carefully. 
Neurophysiological testing of evoked potentials in visual, sensory or auditory pathways can 
also provide supportive evidence of MS by identifying a clinically silent lesion in the CNS 
indicating dissemination in space. A prolonged latency and well-preserved waveform on 
evoked potential testing is suggestive of demyelination but is not specific.16  
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Laboratory investigations are often requested as part of the diagnostic work-up for MS. 
Routine testing for systemic autoimmune diseases has a very low-yield in patients with 
presentations typical of MS.17 Non-specific antibodies are frequently detected that may not 
be clinically relevant with low-titre antinuclear antibodies (ANA) particularly prevalent in 
patients with MS.17 Further targeted laboratory tests to exclude MS mimics might be 
indicated if the history, examination, or MRI findings are atypical.   
   
Diagnostic criteria for MS and their application in clinical settings 
The diagnosis of MS requires objective evidence of CNS lesions disseminated in time and 
space. Historically, this has been on the basis of clinical findings alone requiring two 
separate attacks with signs of two or more lesions.18 The current diagnostic criteria for MS, 
the McDonald 2010 criteria, are shown in Panel 1. Using the McDonald 2010 criteria a 
diagnosis of MS can still be made on clinical grounds alone; however, MRI is used to provide 
evidence for dissemination in time and space, including in patients with CIS.1 For RRMS, 
MRI evidence of dissemination in space requires ≥1 T2 lesion in at least two of four sites – 
periventricular, juxtacortical, and infratentorial regions and the spinal cord (Figure 1), with 
symptomatic lesions in the brainstem and spinal cord excluded.1 Dissemination in time 
requires either asymptomatic gadolinium-enhancing and non-enhancing lesions on the same 
MRI scan or a new lesion on a follow up scan.1 Using the McDonald 2010 criteria a 
diagnosis of RRMS can be made in up to one third of CIS patients with a single MRI scan.19  
 
The McDonald criteria provide separate recommendations for the diagnosis of PPMS which 
include CSF abnormalities in addition to MRI.1 Brain T2 lesion load tends to be lower in 
PPMS6 and the combination of MRI and CSF findings provides a higher sensitivity than MRI 
alone.20 Dissemination in space in suspected PPMS requires two or more of the following: 
(1) ≥1 T2 brain lesion in at least one of the three sites typically affected in MS 
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(periventricular, juxtacortical, infratentorial); (2) ≥2 T2 spinal cord lesions; (3) positive CSF 
(≥2 OCBs not present in serum, raised IgG index, or both). Progressive worsening over a 
period of at least 12 months provides evidence of dissemination in time. 
 
The McDonald 2010 criteria are easily applied in a clinical setting and allow for an earlier 
diagnosis of MS.19 However, there are important caveats when using MRI criteria to 
diagnose MS. Firstly, the criteria are intended for use in patients in whom a diagnosis of MS 
is clinically suspected, rather than to differentiate MS from other neurological disorders. MRI 
in patients with small-vessel cerebrovascular disease, other inflammatory and non-
inflammatory disorders affecting white matter (see examples in Tables 2 & 3), and even in 
healthy subjects (especially in older age groups), may show brain lesions that fulfil MRI 
criteria for MS21-24 The McDonald MRI criteria were developed and tested in CIS patients 
with symptoms typical of MS (e.g. unilateral optic neuritis) and they should not be applied to 
patients with non-specific neurological symptoms such as paraesthesia, dizziness or 
headache, in which the diagnosis is much less likely.23 Secondly, MRI criteria were tested 
and validated in European populations with a high incidence of MS25, although recent 
studies investigating the McDonald 2010 criteria in CIS cohorts in Latin America26 and Asia27 
have reported a similarly good performance. Finally the diagnosis of MS should only be 
made by a neurologist taking into account the clinical picture, MRI findings and the results of 
any other investigations. 
 
The radiologically isolated syndrome 
The widespread use of MRI means incidental findings suggestive of MS are sometimes 
identified in some people who have no clinical symptoms. This is referred to as a 
radiologically isolated syndrome (RIS).28 The typical demyelinating lesions that characterise 
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RIS need to be carefully differentiated from small-vessel cerebrovascular disease and non-
specific white matter lesions (the latter being common in people with migraine21,24). 
 
A third of RIS patients will develop clinical symptoms in the first 5 years of follow up (either a 
relapse or progressive symptoms).29 Younger age, male gender and gadolinium-enhancing, 
cortical or spinal cord lesions may be associated with an increased risk of developing MS.29-
31 There are no accepted diagnostic criteria for RIS, but the Okuda 2009 criteria28 have been 
used in research studies and can also be applied in a clinical setting. These criteria consider 
only dissemination in space and are more stringent than the McDonald criteria, taking into 
account lesion size and morphology as well as location to help differentiate asymptomatic 
demyelinating lesions from other white matter lesions. 
 
At this time it is considered essential that a diagnosis of MS only be made in a patient who 
has symptoms suggestive of demyelination.2 However, patients with RIS are at significant 
risk for developing MS and should be counselled and offered follow up as appropriate. 
 
MS in special patient populations      
MS in children  
Up to 5% of people with MS develop their first symptoms in childhood, almost always 
RRMS.32 In younger children (<12 years) MS may present differently from adolescents and 
adults; encephalopathy, multifocal neurological deficits (often with prominent 
brainstem/cerebellar involvement) and seizures are more common.32 MRI findings may 
include large, confluent T2-hyperintense lesions that show remarkable resolution on follow-
up scans.33 The clinical features and MRI findings may be suggestive of ADEM (see below). 
Older children (≥12 years) usually present with clinical features and MRI findings similar to 
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adults with CIS.32,34 The performance of the McDonald 2010 criteria has been tested in 
children with CIS and the criteria have a similar sensitivity/specificity for the development of 
MS as in adult populations35 but should not be applied in the setting of encephalopathy (i.e. 
ADEM).32  
 
MS in older adults 
People presenting with MS after the age of 50 years have typically been classified as having 
late-onset multiple sclerosis.36 In this age group males are over-represented and a 
progressive onset is more common. Establishing a diagnosis of MS can be more difficult in 
older adults because white matter lesions due to small-vessel cerebrovascular disease are 
frequently found on brain MRI.7,37 In this situation a stringent interpretation of brain MRI 
criteria for MS is mandatory and spinal cord MRI is helpful since spinal cord lesions do not 
occur with healthy aging.11 A CSF examination looking for OCBs can also be particularly 
helpful in older adults, as may visual evoked potentials. Studies investigating MRI criteria for 
a diagnosis of MS have typically excluded patients older than 50 years and the McDonald 
criteria have not been investigated in this group.  
 
Atypical demyelinating lesions 
Brain lesions in MS are typically small (<1cm diameter) and ovoid with a homogenous signal 
on T2-weighted sequences.9 Occasionally, MS presents with an atypical demyelinating 
lesion characterised by their large size (>2cm diameter, sometimes with peri-lesional 
oedema and mass effect), enhancement pattern (open or closed-ring enhancement) or 
morphology (infiltrative or heterogeneous appearance including concentric rings).38-40  These 
lesions may have the appearance of a neoplasm (glioma, primary CNS lymphoma) or 
infection (brain abscess, progressive multifocal leukoencephalopathy), sometimes 
necessitating brain biopsy. While some patients presenting with atypical demyelinating 
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lesions have a monophasic course, 30-60% develop MS.38,40 MRI might help predict 
outcome; the presence of typical MS lesions and a closed-ring enhancement pattern have 
been associated with a higher risk of MS.38 Atypical demyelinating lesions are also seen in 
NMOSD and ADEM. 41 
  
Differential diagnosis of MS  
The differential diagnosis of MS is broad and many neurologists use the approach of 
identifying “red flag” clinical, imaging or other laboratory features that suggest an alternative 
diagnosis.42 The differential diagnosis depends on the clinical presentation with different 
considerations in patients with relapsing or progressive courses. These disorders include 
several closely related idiopathic inflammatory CNS diseases, along with a range of other 
disorders that may involve white matter including inherited leukodystrophies, vasculopathies, 
metabolic disorders and other neuroinflammatory diseases (e.g. sarcoidosis, vasculitis, 
Behcet’s disease). Although a comprehensive differential diagnosis is beyond this review, 
Tables 2 and 3 provide further information on a limited number of disorders that, in our 
experience, can be confused with MS. Selected idiopathic inflammatory disorders in which 
demyelination is a feature are discussed in more detail below.  
 
Acute disseminated encephalomyelitis (ADEM) 
ADEM is an inflammatory demyelinating disorder of the CNS distinct from MS that occurs 
mainly in childhood and is rare in adults. Patients present with multifocal neurological deficits 
and encephalopathy sometimes with a history of antecedent infection or vaccination. MRI 
findings include large (>1-2cm), bilateral white matter lesions and deep grey matter lesions 
and contrast enhancement.42 CSF findings include a lymphocytic pleocytosis and raised 
protein. CSF OCBs may only be present transiently. The clinical, imaging and laboratory 
features of ADEM and MS overlap and diagnostic criteria emphasise the requirement of 
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encephalopathy (altered level of consciousness, behavioural or cognitive change) in making 
the diagnosis of ADEM (Supplementary Panel 1).32 ADEM is almost always monophasic; 
however, an encephalopathic ADEM-like illness can sometimes be the first presentation of 
MS in both children32,34 and adults43 and diagnostic criteria for ADEM remain imperfect. 
 
Neuromyelitis optica spectrum disorder (NMOSD) 
NMOSD is an inflammatory astrocytopathy of the CNS with clinical and radiological features 
that overlap with MS.4 The identification of a pathogenic IgG antibody directed against the 
aquaporin-4 (AQP4-IgG) water channel has established NMOSD as a specific disease entity 
that needs to be differentiated from MS because of important differences in prognosis and 
treatment.44,45 NMOSD is approximately 100 times less common than MS in European and 
North American populations but is relatively more common in Asia and Africa where MS is 
less common.46 NMOSD shows a strong gender bias (female:male ratio up to 9:1) and a 
mean age at onset of 39 years46, although all age groups can be affected including children 
and the elderly. A history of autoimmunity including thyroid disease and connective tissue 
disorders (e.g. systemic lupus erythematosus, Sjogren’s syndrome) is not uncommon.45 
Most patients with NMOSD have a relapsing course with accumulation of disability over time 
related to poor recovery from individual attacks and a secondary progressive course is 
rare.45,47 An accurate diagnosis of NMOSD is essential since prompt treatment of acute 
attacks and long-term immunosuppression appear to reduce disability, while conventional 
MS treatments may aggravate NMOSD.44,48  
 
The core clinical features of NMOSD are optic neuritis and transverse myelitis. Compared 
with MS, optic neuritis in NMOSD is more likely to be bilateral (either simultaneous or rapidly 
sequential) and associated with poor visual recovery. Lesions extending over more than half 
the length of the optic nerve, and sometimes into the optic chiasm are characteristic of 
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NMOSD.49,50 Attacks of myelitis are associated with longitudinally-extensive spinal cord 
lesions on MRI (≥3 vertebral bodies) with prominent involvement of the central cord49 
(Supplementary Figure 4), in contrast to MS where lesions are usually short (<1-2 vertebral 
bodies) and located peripherally. Brain involvement also occurs in NMOSD especially in 
areas rich in aquaporin-4 such as the dorsal medulla/area postrema (where lesions may 
cause intractable nausea, vomiting and hiccoughs), diencephalon, and periependymal 
regions of the corpus callosum, third and fourth ventricles (Supplementary Figure 1).49 
Recently it has been recognised that some patients with NMOSD have brain lesions that 
may be difficult to distinguish from MS, with up to a quarter fulfilling Barkhof criteria.51 51 CSF 
occasionally shows features distinct from MS (white cell count >50 cells/cm3, neutrophils or 
eosinophils >5 cells/cm3); however, a mild CSF pleocytosis is more common (white cell 
count <25 cells/cm3).52 In contrast to MS CSF OCBs are uncommon in patients with NMOSD 
(<20%).52  
 
Approximately 70% of patients with relapsing NMOSD are AQP4-IgG positive, with the 
sensitivity increased with the use of cell-based rather than ELISA assays.53,54 AQP4-IgG is 
highly specific for NMOSD, although false positives occur in up to 0.5% of MS patients using 
ELISA assays, potentially resulting in misdiagnosis.54,55 A recently identified subgroup of 
AQP4-IgG seronegative NMOSD patients have antibodies against myelin oligodendrocyte 
glycoprotein (MOG-IgG)56 and may have a more favourable course.50,57 MOG-IgG is also 
found in  some patients with ADEM (particularly in children), and in ADEM followed by optic 
neuritis, and isolated or recurrent optic neuritis.58,59 It is not clear whether MOG-IgG-
associated inflammatory demyelinating syndromes will remain part of NMOSD or be 
considered as a distinct nosologic entity in the future.60 
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Diagnostic criteria for NMOSD have recently been updated (Supplementary Panel 2 ).47 The 
diagnostic criteria are more stringent in AQP4-IgG negative patients requiring at least two 
attacks affecting different sites, one of which must be optic neuritis, myelitis or an area 
postrema syndrome.  
 
Although the first attack of NMOSD can mimic CIS (e.g. acute unilateral optic neuritis or 
short-segment partial myelitis61), routine testing for AQP4-IgG in CIS populations with a high 
incidence of MS and low incidence of NMOSD has a very low yield and is not 
recommended.62 A first demyelinating event suggestive of NMOSD (e.g. severe or bilateral 
optic neuritis, longitudinally-extensive transverse myelitis, area postrema syndrome) should 
always mandate testing for AQP4-IgG and facilitates an earlier diagnosis and treatment. 
  
Misdiagnosis of multiple sclerosis 
Rates of misdiagnosis of MS may be as high as 10%.63 In a survey of MS specialist 
neurologists in the United States, 95% of respondents had seen one or more patients in the 
previous year who had been misdiagnosed with MS, many of whom were being treated 
inappropriately with disease-modifying therapies. The major disorders identified that were 
misdiagnosed as MS were small-vessel cerebrovascular disease, migraine, fibromyalgia and 
functional neurological disorders.64 These disorders usually present quite differently to MS 
and reasons for misdiagnosis included misinterpretation of clinical findings (symptoms not 
typical of demyelination, absence of objective neurological signs) and inappropriate 
application of MRI criteria.63 The application of McDonald criteria and the diagnosis of MS 
should be undertaken by neurologists who are familiar with MS with additional expert advice 
when needed (e.g. MRI review by a neuroradiologist).  
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Controversies and areas of uncertainty 
Although there has been major progress in diagnosing MS, areas of uncertainty remain. The 
role of spinal cord imaging65 and CSF examination66 in MS diagnosis is particularly 
controversial. Current guidelines recommend spinal cord MRI in patients with symptoms of 
myelopathy or when brain MRI findings are not diagnostic of MS.12 However, spinal cord 
lesions can be very helpful in making a diagnosis of MS (cord lesions do not occur with 
healthy aging or cerebrovascular disease11 and provide additional evidence of dissemination 
in space10) and may provide important prognostic information.67 Therefore routine imaging of 
the whole spinal cord in all patients with suspected MS has recently been proposed.68 The 
McDonald 2010 criteria do not mandate a CSF examination and there is much variation 
between neurologists as to how often a lumbar puncture is done in in the diagnosis of MS.66 
As noted previously the sensitivity of OCBs is <100% and may be significantly lower in 
people with a first demyelinating event15, the time when a lumbar puncture is most likely to 
be performed. However, OCBs may provide additional prognostic information15 and may 
increase diagnostic confidence, especially when considering long-term disease-modifying 
treatment.  
 
Gadolinium-enhancing lesions provide evidence for dissemination in time and can also 
assist in differential diagnosis.1,12 Current guidelines recommend a post-contrast T1-
weighted scan as part of the diagnostic evaluation of patients with suspected MS.12 The 
United States Food and Drug Administration and the European Medicines Agency are 
investigating the clinical significance of gadolinium deposits in the brain reported in some 
patients after the repeated use of gadolinium-based contrast agents.69,70 At this time, the 
safety concern should not preclude the use of gadolinium-based contrast agents for 
diagnostic purposes but should be considered in monitoring patients with MS.  
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MRI criteria for MS require a balance between sensitivity (diagnosing MS at an early stage) 
and specificity (making an accurate diagnosis). The optimal balance of sensitivity and 
specificity using MRI criteria is uncertain. Using the McDonald criteria, MS is being 
diagnosed significantly earlier than with the use of clinical criteria alone facilitating earlier 
treatment.19 However, the criteria are intended to provide diagnostic rather than prognostic 
information. Conventional brain MRI findings around the time of diagnosis are only modestly 
predictive of long-term disability8 and there is uncertainty as to the extent to which criteria for 
diagnosis and treatment should be linked. The McDonald criteria identify a subgroup of 
patients with a single attack and MRI evidence of dissemination in time and space who do 
not experience further relapses even with long-term follow-up.71 In the past this group would 
be considered to have CIS rather than MS. The changes to the diagnostic criteria may be 
favourably shifting the apparent long-term outcome of MS (the so called “Will Rogers 
phenomenon”), independent of any effect of disease-modifying treatments.72  
 
Conclusions and future perspectives 
Current diagnostic criteria for MS integrate clinical and MRI findings and enable an earlier 
and more reliable diagnosis of MS than with clinical findings alone, potentially facilitating 
earlier treatment.  The criteria are best applied in an individual patient when there are typical 
symptoms and signs of MS and when relevant differential diagnoses have been excluded. 
Further supportive information from CSF and/or evoked potentials can be obtained if 
diagnostic uncertainty remains. 
 
Despite the current usefulness of the McDonald criteria, the MAGNIMS network have 
recently proposed a number of modifications, such as inclusion of optic nerve, cortical and 
symptomatic lesions in dissemination in space and standardisation of dissemination in space 
criteria for RRMS, PPMS and RIS.68 Some of these recommendations are evidence-
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based73,74 and others are based on expert consensus. These and other changes to the 
diagnostic criteria for MS will be considered at a meeting of an international panel in late 
2016. 
 
Further iterations of the McDonald criteria may allow for inclusion of new and emerging MRI 
techniques with improved pathological specificity.12,68 Cortical grey matter is frequently 
involved in MS pathologically, but cortical lesions are rarely visualised on conventional MRI 
sequences and are better seen using double inversion recovery (DIR) or phase-sensitive 
inversion recovery (PSIR) techniques.73,75 Cortical grey matter lesions may be helpful in 
making a diagnosis of MS68,73 and have not been found in NMOSD76 or migraine.24 MS 
lesions characteristically have a perivenular distribution and using T2* or susceptibility-
weighted imaging a central vein can be detected in most MS lesions, especially at higher 
field strengths.77 The presence of a “central vein sign” might help differentiate MS from 
NMOSD78 and white matter lesions due to small vessel disease, migraine, and healthy 
aging.77 Research is also focused on novel CSF and body fluid biomarkers that are 
associated with the development of MS in patients with CIS including CSF IgM-OCBs, MRZ-
specific IgG, kappa free light chains, CXCL13, chitinase-3-like protein 1 and neurofilament 
light chain.79 However, their utility in differentiating MS from other disorders is yet to be 
established. Optical coherence tomography (OCT) is also being investigated as an MS 
biomarker. Evidence that retinal nerve fibre layer thinning occurs in MS means that OCT has 
potential utility as a predictor of progression from CIS to MS96 and OCT findings may assist 
in differentiating MS from NMOSD80 and Susac’s syndrome.81  
 
The diagnosis of MS and its many differential diagnoses can still be challenging but progress 
continues to be made. Diagnostic criteria for both MS and NMOSD have changed in recent 
years as new pathological, immunological, imaging, clinical and therapeutic findings have 
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emerged. It is likely that there will be future changes in diagnostic criteria for MS and other 
CNS inflammatory disorders as new knowledge and clinical experience evolves.
19 
 
Table 1. Typical presentations of relapsing-remitting MS and selected atypical presentations 
that are more suggestive of an alternative diagnosis.  
Typical  Atypical  
Acute unilateral optic neuritis 
Double vision due to an internuclear  
  ophthalmoplegia or sixth nerve palsy * 
Facial sensory loss or trigeminal neuralgia * 
Cerebellar ataxia and nystagmus 
Partial myelopathy 
- Sensory symptoms 
- Lhermitte’s symptom 
- Asymmetric limb weakness  
- Urge incontinence, erectile dysfunction 
Bilateral optic neuritis, or unilateral optic   
  neuritis with a poor visual recovery 
Complete gaze palsy or fluctuating  
  ophthalmoparesis  
Intractable nausea, vomiting or hiccups  
Complete transverse myelopathy with  
bilateral motor/sensory involvement  
Encephalopathy 
Subacute cognitive decline  
Headache, meningism 
Isolated fatigue / asthenia  
Constitutional symptoms  
* In a young adult (< 40 years)  
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Table 2. Differential diagnosis of multiple sclerosis: selected disorders with a relapsing-
remitting course. 
Disorder Clinical features MRI findings CSF findings Other investigations 
NMOSD Optic neuritis – especially 
bilateral or with visual 
poor recovery 
Transverse myelitis 
Intractable nausea and 
vomiting 
Paroxysmal tonic spasms 
 
Longitudinally-extensive 
optic nerve lesions 
(involving >50% of the 
optic nerve) +/- 
extension into the optic 
chiasm 
Brain lesions in 
diencephalon, dorsal 
midbrain, 
periependymal regions; 
“cloudlike” 
enhancement 
Longitudinally-extensive 
spinal cord lesions 
extending over ≥3 
vertebral segments 
 
Mild CSF pleocytosis 
sometimes with 
neutrophils or 
eosinophils 
OCBs present 20% 
AQP4-IgG  
MOG-IgG  
+/- OCT 
Neurosarcoidosis Optic neuropathy and 
myelopathy; facial palsy 
Early relapse after 
stopping steroids 
+/- Systemic involvement  
Meningeal 
enhancement 
Enhancement of the 
optic nerve sheath 
Persistent, nodular 
enhancement within 
lesions 
Enlarged lacrimal glands 
OCBs sometimes present 
Raised CSF ACE level (not 
sensitive or specific for 
neurosarcoidosis) 
Serum ACE level 
Chest x-ray, HRCT, lung 
function tests 
CT/PET scan 
Slit-lamp examination 
Tissue biopsy 
CNS vasculitis 
(primary or 
secondary) 
Headache, acute CNS 
syndromes including 
hemiparesis and ataxia 
Early cognitive 
impairment 
+/- Systemic involvement 
Punctate or larger 
lesions in the grey and 
white matter, often 
enhancing, sometimes 
with restricted diffusion 
and evidence of micro-
haemorrhages 
OCBs sometimes present 
 
Serum ANCA (systemic 
vasculitis) 
Tissue biopsy – 
systemic site or brain 
biopsy (if possible) 
 
Susac’s syndrome Encephalopathy, visual 
loss, deafness 
“Snow-ball” lesions in 
the corpus callosum 
associated with 
restricted diffusion in 
the acute phase and 
then T1-hypointensity; 
also “icicle” and “spoke” 
lesions 
OCBs usually absent Fluorescein angiogram 
looking for branch 
retinal artery 
occlusions 
OCT 
Audiogram 
CADASIL Migraine, especially with 
complex or prolonged 
aura 
Recurrent acute 
hemiparesis and other 
vascular syndromes 
Neuropsychiatric 
disturbance 
Dementia 
Extensive white matter 
abnormalities; 
prominent involvement 
of the temporal poles 
and external capsule 
OCBs absent Testing for NOTCH3 
gene mutation  
Skin biopsy 
Connective tissue 
disorders (SLE, 
Sjogren’s syndrome, 
antiphospholipid 
syndrome) 
Optic neuritis, 
longitudinally extensive 
transverse myelitis, 
Systemic involvement 
Recurrent miscarriage, 
thrombosis 
(antiphospholipid 
syndrome) 
Variable OCBs usually absent Serologic testing – ANA, 
ENA, antiphospholipid 
antibodies 
AQP4-IgG 
Behcet’s disease Brainstem syndrome, 
myelopathy (rare) 
Oral and genital ulceration 
Intraocular inflammation 
Mass-like enhancing 
lesions, predilection for 
the midbrain, thalami 
and internal capsules 
Significant pleocytosis 
(WCC >50 cells/cm3), may 
be neutrophil 
predominant 
OCBs usually absent 
Pathergy testing 
HLA typing 
CLIPPERS Subacute ataxia, double Punctate gadolinium- OCBs sometimes present Brain biopsy 
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vision and slurred speech 
Early relapse after 
stopping steroids 
 
enhancing lesions within 
the brainstem and 
cerebellum +/- lesions in 
the basal ganglia, 
supratentorial white 
matter and spinal cord 
 
Leber’s hereditary 
optic neuropathy 
 
Bilateral sequential optic 
neuropathies with poor 
visual recovery 
Males > females 
Normal or may show 
white matter lesions 
(Harding’s disease) 
OCBs absent Genetic testing 
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Table 3. Differential diagnosis of multiple sclerosis: selected disorders with a progressive 
course. 
Disorder Clinical features MRI findings CSF findings Other investigations 
HTLV1-associated 
myelopathy 
Progressive myelopathy 
Residence or travel to an 
endemic area (especially 
West Indies, Japan) 
Spinal cord atrophy 
(thoracic > cervical) 
T2-hyperintense brain 
lesions in some patients 
OCBs 
sometimes 
present 
 
CSF HTLV1 antibody testing 
Dural AV fistula Subacute, progressive 
myelopathy 
Extensive spinal cord T2-
hyperintensity often 
extending to the conus +/- 
gadolinium enhancement  
Dilated veins over the 
dorsal surface of the cord 
(often subtle) 
Brain MRI normal 
OCBs absent Spinal angiogram 
Nutritional myelopathy 
(vitamin B12 or copper 
deficiency) 
Subacute progressive 
myelopathy or 
myeloneuropathy 
Optic atrophy (severe B12 
deficiency) 
Anaemia or pancytopenia 
T2-hyperintensity upper 
cervical cord classically 
affecting the posterior 
columns 
Brain MRI normal 
OCBs absent Serum B12, methylmalonic 
acid 
Serum copper levels, 
caeruloplasmin 
Primary lateral sclerosis  
(or upper motor neurone 
predominant ALS) 
Spastic quadriparesis or 
hemiparesis 
+/- Bulbar involvement 
+/- Development of lower 
motor neurone signs 
MRI normal or showing T2-
hyperintensity in the 
corticospinal tracts 
OCBs absent EMG looking for lower 
motor neurone 
involvement 
Leukodystrophies 
- Adrenomyeloneuropathy 
- Krabbe’s disease 
- Alexanders disease 
- Hereditary diffuse 
leukoencephalopathy 
with axonal spheroids 
(HDLS) 
Progressive myelopathy 
(adrenomyeloneuropathy, 
Krabbe’s) 
Bulbar symptoms, ataxia 
(Alexander’s disease)  
Early cognitive impairment 
(HDLS) 
 
Highly variable 
Diffuse, symmetrical T2-
hyperintensity sparing 
subcortical U fibres; with 
posterior hemispheric 
predominance 
(adrenomyeloneuropathy)  
Spinal cord MRI normal or 
showing atrophy 
OCBs absent Very-long chain fatty acids 
(adrenomyeloneuropathy) 
 
Genetic testing available 
for some leukodystrophies 
Hereditary spastic 
paraplegia  
(especially SPG5) 
Slowly progressive 
myelopathy 
(spasticity>weakness) 
+/- Other neurological 
symptoms 
+/- Family history 
Spinal cord atrophy 
Supratentorial and 
infratentorial white matter 
lesions (SPG5) 
Atrophy of the corpus 
callosum 
OCBs absent Genetic testing 
Spinocerebellar ataxias Progressive cerebellar 
ataxia  
+/- Other neurological 
symptoms 
+/- Family history 
Early, prominent cerebellar 
+/- spinal cord atrophy 
OCBs absent Genetic testing 
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Panel 1. McDonald 2010 diagnostic criteria for multiple sclerosis (modified from Polman et al 20111) 
 
Clinical scenario 
 
Additional evidence required 
≥2 attacks with objective evidence of 
≥2 lesions 
None 
≥2 attacks with objective evidence of 
1 lesion 
Dissemination in space demonstrated by: 
- ≥1 T2 lesion in at least 2 of 4 areas of the CNS typically affected in 
demyelination: periventricular, juxtacortical, infratentorial, spinal cord 
(Figure 1) 
- Second clinical attack at a different site 
1 attack with objective evidence of 
≥2 lesions 
Dissemination in time demonstrated by: 
- Simultaneous presence of asymptomatic gadolinium-enhancing and 
nonenhancing lesions on a single scan or a new T2 and/or gadolinium-
enhancing lesion on follow-up MRI (Figure 2) 
- Second clinical attack 
1 attack with objective evidence of 1 
lesion 
Dissemination in space demonstrated by: 
- ≥1 T2 lesion in at least 2 of 4 areas of the CNS typically affected in 
demyelination: periventricular, juxtacortical, infratentorial, spinal cord 
- Second clinical attack at a different site 
 
Dissemination in time demonstrated by 
- Simultaneous presence of asymptomatic gadolinium-enhancing and 
nonenhancing lesions on a single scan or a new T2 and/or gadolinium-
enhancing lesion on follow-up MRI (Figure 2) 
- Second clinical attack 
 
One year of disease progression 
(retrospectively or prospectively 
determined) 
Two of the following: 
- ≥1 T2 brain lesions in at least one MS-characteristic regions 
(periventricular, juxtacortical, or infratentorial)  
- ≥2 T2 spinal cord lesions 
- Positive CSF (≥2 oligoclonal bands not present in serum, elevated 
IgG index, or both) 
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Figure 1. Locations of typical multiple sclerosis lesions in the brain and spinal cord indicated 
by white arrows. Axial brain MRI scans showing multiple periventricular lesions (a) with 
contrast enhancement of one lesion (b), juxtacortical lesions (c) and infratentorial lesions (d). 
Sagittal (e,f) and axial (g,h) scans with a cervical spinal cord lesion showing contrast 
enhancement in (f,h) 
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Supplementary Panel 1. Diagnostic criteria for acute disseminated encephalomyelitis (modified from 
Krupp et al 201332) 
1. A first polyfocal, clinical CNS event with presumed inflammatory demyelinating cause 
2. Encephalopathy that cannot be explained by fever 
3. No new clinical and MRI findings emerge three months or more after the onset 
4. Brain MRI is abnormal during the acute (three-month) phase. Typical brain MRI findings include: 
 Diffuse, poorly demarcated, large (>1–2 cm) lesions involving predominantly the cerebral 
white matter 
 T1 hypointense lesions in the white matter are rare 
 Deep grey matter lesions (e.g. thalamus or basal ganglia) can be present 
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Supplementary Panel 2. Neuromyelitis optica spectrum disorder (modified from Wingerchuk et al 20154) 
Core clinical characteristics 
1. Optic neuritis 
2. Acute myelitis 
3. Area postrema syndrome (an episode of otherwise unexplained hiccups or nausea and vomiting) 
4. Acute brainstem syndrome 
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions  
6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions  
Diagnostic criteria for NMOSD with AQP4-IgG 
1. At least 1 core clinical characteristic 
2. Positive test for AQP4-IgG using best available detection method 
3. Exclusion of alternative diagnoses 
Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-IgG status 
1. At least 2 core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements: 
 a. At least 1 core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndrome 
 b. Dissemination in space (2 or more different core clinical characteristics) 
 c. Fulfilment of additional MRI requirements, as applicable (see Wingerchuk et al 20154) 
2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable 
3. Exclusion of alternative diagnoses 
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Supplementary Figure 1. T2-weighted MRI scans in AQP4-IgG positive neuromyelitis optica 
spectrum disorder (NMOSD). 
B 
A B 
C D 
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(A) a longitudinally extensive spinal cord lesion (arrows); (B) a lesion involving the central 
spinal cord (arrow heads); (C) a lesion in the dorsal medulla (arrow); (D) multifocal lesions 
around the lateral ventricles, third ventricle and diencephalon. 
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Search strategy and selection criteria 
We searched MEDLINE (01 January 1995 – 15 May 2016) using the search terms “multiple 
sclerosis”, “neuromyelitis optica”, “acute disseminated encephalomyelitis, “diagnosis”, 
“diagnostic criteria” and “differential diagnosis” for articles published in the English language. 
Additional articles were also sought from the reference lists of relevant articles. Priority was 
given to new studies published in the last 5 years. Where appropriate review articles have 
been referenced to provide more detailed information on individual topics.  
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